CNTX - Context Therapeutics Inc logo

Context Therapeutics Inc

CNTX

Context Therapeutics Inc. develops biopharmaceutical products for treating solid tumors, focusing on therapies like the bispecific antibody CTIM-76 that targets malignant cells. The company collaborates with Integral Molecular for cancer therapy advancements.

โš•๏ธ Healthcare NASDAQ Listed 2021 $ USD
$1,000 invested 5 years ago โ†’$34today

Score Overview

1 Year
Scoreโ€”
Net Growth-27.22%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Scoreโ€”
Net Growth-339.50%
Net TrendNever
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendNever
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth-339.50%
Net TrendNever
Net Income Consistency
Rev Growthโ€”
Rev TrendNever
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Context Therapeutics Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. CNTX does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-23
$ 0.24โ€”
1 Year2025-10-23
$ 1.28-81.30%
5 Years2021-10-22
$ 6.99-96.58%
All Time2021-10-20
$ 5.10-95.31%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 0.00-$ 45M$ 42M
2025$ 0.00-$ 36M$ 65M
2024$ 0.00-$ 26M$ 94M
2023$ 0.00-$ 23M$ 14M
2022$ 0.00-$ 14M$ 35M
IPO2021$ 0.00-$ 10M$ 49M
CNTX - Context Therapeutics Inc logo

Context Therapeutics Inc fundamental performance

Across Context Therapeutics Inc's full reported history, from 2021 to 2025, revenue held from $ 0.00 to $ 0.00 and net income went from -$ 10M to -$ 36M. Revenue increased in 0% of the years measured; net income in 0%.

Membership

Explore CNTX with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,112 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies